Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many
people perceive breast cancer to be the number one threat to women's health. CVD and …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

Objectives: The aim of this study was to evaluate whether cardiac biomarkers, tissue velocity
(TVI) and strain imaging, and cardiac magnetic resonance imaging can predict early left …

Cardiotoxicity of anticancer treatments has become an increasingly important clinical
problem faced by cardiologists. Left ventricular systolic dysfunction and heart failure …

Doxorubicin (DOX) is a kind of representative anthracyclines. It has greatly prolonged
lifespan of cancer patients. However, a long course of DOX chemotherapy could induce …

Patients with or receiving potentially cardiotoxic treatment for cancer are susceptible to
develo** decrements in left ventricular mass, diastolic function, or systolic function. They …

Objectives To review the evidence for the use of various biomarkers in the detection of
chemotherapy associated cardiac damage. Design and methods Pubmed. gov was queried …